Research

Hormonal

Roux-en-Y gastric bypass (RYGB) induces significant remission of Type 2 Diabetes (T2DM) and Systemic Arterial Hypertension (SAH) in obese patients, largely through neuroendocrine mechanisms involving GLP-1 and bile acids, independent of or in addition to weight loss.

For obese patients with difficult-to-control diabetes or hypertension, Roux-en-Y gastric bypass is a highly effective treatment that can lead to disease remission. This benefit is driven by hormonal changes in the gut (GLP-1 and bile acids) that improve metabolic control, not just by weight loss. While lifestyle changes are the first line of defense, they often fail to sustain control, making surgery a viable option for eligible candidates.

ModerateSupportsMEDIUM confidence
This is due to changes in neuroendocrine mechanisms mediated by glucagon-like peptide 1 (GLP-1) and changes in intestinal physiology, exerting a regulatory effect under glycemic control, regardless of weight loss
Giulia Marchetti et al. · Revista do Colégio Brasileiro de Cirurgiões · 2020

Why this rating

Retrospective cohort study with a large sample size (n=252) but limited follow-up (2 years) and lack of a concurrent control group for the specific surgical vs. medical comparison within the study itself.

Source

The effect of Roux-en-Y gastric bypass in the treatment of hypertension and diabetes

Giulia Marchetti et al. · Revista do Colégio Brasileiro de Cirurgiões · 2020

DOI 10.1590/0100-6991e-20202655

cohort · n=252Cited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →